The Induction of Macrophage Endoplasmic Reticulum Stress by Irradiated-Tumor Derived Extracellular Vesicles Supports the Adoption of a Pro-Tumor Phenotype

辐射肿瘤源性细胞外囊泡对巨噬细胞内质网应激的诱导支持了亲肿瘤表型的采用

基本信息

  • 批准号:
    9760846
  • 负责人:
  • 金额:
    $ 3.77万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2019
  • 资助国家:
    美国
  • 起止时间:
    2019-05-15 至 2024-05-14
  • 项目状态:
    已结题

项目摘要

Project Summary Radiotherapy initiates the recruitment of alternatively stimulated (M2) macrophages to the tumor microenvironment. These cells exhibit a “pro-tumor phenotype,” stimulating angiogenesis, suppressing anti- tumor immunity, and enhancing tumor cell radioresistence. This limits the overall efficacy of radiotherapy for solid tumors such as non-small cell lung cancer. Current research in the field of radioimmunology is focused on manipulations that either inhibit the recruitment of these cells or that alter their behavior once they reach the tumor microenvironment. However, exactly how irradiated cancer cells manipulate macrophages is largely unknown. We have discovered that extracellular vesicles elaborated by irradiated lung cancer cells (IR-EVs) induce ER-stress and elicit the production of “pro-tumor” cytokines from macrophages in an SRA/CD204 dependent manner. The overall objective of this project is to define the molecular mechanisms by which IR-EVs induce macrophage pro-tumor cytokine expression. First, we will test the functional impact of IR-EV induced macrophage ER stress on macrophage phenotype using CHOP-/- C57BL/6 mice and soluble inhibitors of ER stress. Then, we will investigate the role of macrophage SRA/CD204 in the response of macrophages to IR-EVs. We will do this using SRA/CD204-/- C57BL/6 mice as well as a novel SRA/CD204 blocking antibody developed in our laboratory. Finally, we will compare the circulating IR-EVs of recurrent and non-recurrent non-small cell lung cancer patients to determine if they can predict the outcome of radiotherapy. EVs from recurrent and non- recurrent NSCLC patients isolated before, during, and after RT will be assessed for their ability to stimulate a pro-tumor macrophage phenotype in vitro. Then, mass spectrometry will be used to identify a potential SRA/CD204 binding protein upregulated on the surface of IR-EVs from patients and cultured cells. The potential of ligand bearing exosomes to segregate lung cancer patients into relapse or disease-free survival groups will be evaluated using a commercially available ELISA on concentrated serum exosomes.
项目摘要 放射治疗启动了交替刺激(M2)巨噬细胞向肿瘤的募集 微环境这些细胞表现出“促肿瘤表型”,刺激血管生成,抑制抗肿瘤活性。 增强肿瘤细胞的抗辐射能力。这限制了放射治疗的总体疗效, 实体瘤如非小细胞肺癌目前放射免疫学领域的研究主要集中在 这些操作要么抑制这些细胞的募集,要么一旦它们到达细胞膜就改变它们的行为。 肿瘤微环境然而,辐射癌细胞如何操纵巨噬细胞在很大程度上是未知的。 未知我们已经发现,照射后的肺癌细胞(IR-EVs) 诱导ER应激并引发SRA/CD 204中巨噬细胞产生“促肿瘤”细胞因子 依赖的方式。本项目的总体目标是确定IR-EV的分子机制, 诱导巨噬细胞促肿瘤细胞因子表达。首先,我们将测试IR-EV诱导的功能影响。 使用CHOP-/-C57 BL/6小鼠和可溶性ER抑制剂对巨噬细胞表型巨噬细胞ER应激 应力然后,我们将研究巨噬细胞SRA/CD 204在巨噬细胞对IR-EV的反应中的作用。 我们将使用SRA/CD 204-/-C57 BL/6小鼠以及开发的新型SRA/CD 204阻断抗体来实现这一点。 在我们的实验室里。最后,我们将比较复发性和非复发性非小细胞肺癌的循环IR-EV。 肺癌患者,以确定他们是否可以预测放疗的结果。来自经常性和非经常性 在RT之前、期间和之后分离的复发性NSCLC患者将评估其刺激肿瘤细胞增殖的能力。 体外促肿瘤巨噬细胞表型。然后,质谱分析将被用来识别一个潜在的 SRA/CD 204结合蛋白在来自患者和培养细胞的IR-EV表面上上调。的潜在 携带配体的外泌体将肺癌患者分为复发或无病生存组, 使用市售ELISA对浓缩的血清外泌体进行评价。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Gene Chatman Clark 其他文献

Gene Chatman Clark 的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Gene Chatman Clark ', 18)}}的其他基金

The Induction of Macrophage Endoplasmic Reticulum Stress by Irradiated-Tumor Derived Extracellular Vesicles Supports the Adoption of a Pro-Tumor Phenotype
辐射肿瘤源性细胞外囊泡对巨噬细胞内质网应激的诱导支持了亲肿瘤表型的采用
  • 批准号:
    10386821
  • 财政年份:
    2019
  • 资助金额:
    $ 3.77万
  • 项目类别:
The Induction of Macrophage Endoplasmic Reticulum Stress by Irradiated-Tumor Derived Extracellular Vesicles Supports the Adoption of a Pro-Tumor Phenotype
辐射肿瘤源性细胞外囊泡对巨噬细胞内质网应激的诱导支持了亲肿瘤表型的采用
  • 批准号:
    10611841
  • 财政年份:
    2019
  • 资助金额:
    $ 3.77万
  • 项目类别:

相似海外基金

WELL-CALF: optimising accuracy for commercial adoption
WELL-CALF:优化商业采用的准确性
  • 批准号:
    10093543
  • 财政年份:
    2024
  • 资助金额:
    $ 3.77万
  • 项目类别:
    Collaborative R&D
Investigating the Adoption, Actual Usage, and Outcomes of Enterprise Collaboration Systems in Remote Work Settings.
调查远程工作环境中企业协作系统的采用、实际使用和结果。
  • 批准号:
    24K16436
  • 财政年份:
    2024
  • 资助金额:
    $ 3.77万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Unraveling the Dynamics of International Accounting: Exploring the Impact of IFRS Adoption on Firms' Financial Reporting and Business Strategies
揭示国际会计的动态:探索采用 IFRS 对公司财务报告和业务战略的影响
  • 批准号:
    24K16488
  • 财政年份:
    2024
  • 资助金额:
    $ 3.77万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 3.77万
  • 项目类别:
    EU-Funded
Assessing the Coordination of Electric Vehicle Adoption on Urban Energy Transition: A Geospatial Machine Learning Framework
评估电动汽车采用对城市能源转型的协调:地理空间机器学习框架
  • 批准号:
    24K20973
  • 财政年份:
    2024
  • 资助金额:
    $ 3.77万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 3.77万
  • 项目类别:
    EU-Funded
Our focus for this project is accelerating the development and adoption of resource efficient solutions like fashion rental through technological advancement, addressing longer in use and reuse
我们该项目的重点是通过技术进步加快时装租赁等资源高效解决方案的开发和采用,解决更长的使用和重复使用问题
  • 批准号:
    10075502
  • 财政年份:
    2023
  • 资助金额:
    $ 3.77万
  • 项目类别:
    Grant for R&D
Engage2innovate – Enhancing security solution design, adoption and impact through effective engagement and social innovation (E2i)
Engage2innovate — 通过有效参与和社会创新增强安全解决方案的设计、采用和影响 (E2i)
  • 批准号:
    10089082
  • 财政年份:
    2023
  • 资助金额:
    $ 3.77万
  • 项目类别:
    EU-Funded
De-Adoption Beta-Blockers in patients with stable ischemic heart disease without REduced LV ejection fraction, ongoing Ischemia, or Arrhythmias: a randomized Trial with blinded Endpoints (ABbreviate)
在没有左心室射血分数降低、持续性缺血或心律失常的稳定型缺血性心脏病患者中停用β受体阻滞剂:一项盲法终点随机试验(ABbreviate)
  • 批准号:
    481560
  • 财政年份:
    2023
  • 资助金额:
    $ 3.77万
  • 项目类别:
    Operating Grants
Collaborative Research: SCIPE: CyberInfrastructure Professionals InnoVating and brOadening the adoption of advanced Technologies (CI PIVOT)
合作研究:SCIPE:网络基础设施专业人员创新和扩大先进技术的采用 (CI PIVOT)
  • 批准号:
    2321091
  • 财政年份:
    2023
  • 资助金额:
    $ 3.77万
  • 项目类别:
    Standard Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了